Market Overview
The Europe gene therapy market was valued at USD 2.5 Billion in 2024 and is anticipated to grow to USD 7.3 Billion by 2033, reflecting a CAGR of 12% during the forecast period of 2025-2033. This growth is primarily driven by significant advancements in gene editing technologies, rising prevalence of genetic disorders, and increased investment in research and development activities. Europe hosts leading research institutions with over 250 ongoing clinical trials, making it a hub for innovation in gene therapy.
Study Assumption Years
- Base Year: 2024
- Historical Years/Period: 2019-2024
- Forecast Years/Period: 2025-2033
Europe Gene Therapy Market Key Takeaways
- Current Market Size: USD 2.5 Billion in 2024
- CAGR: 12% during 2025-2033
- Forecast Period: 2025-2033
- Europe is home to leading research institutions and universities driving advancements in gene therapy.
- More than 250 ongoing clinical trials are focused on cell and gene therapies across the region.
- Biopharmaceutical firms in Germany are heavily investing in research, clinical trials, and partnerships to accelerate product development.
- Advancements in gene-editing tools and vector design are enhancing treatment precision, safety, and scalability.
- Rising prevalence of genetic disorders and cancers in countries like Italy is fueling demand for advanced gene therapy treatments.
Sample Request Link: https://www.imarcgroup.com/Europe-Gene-Therapy-Market/requestsample
Market Growth Factors
The growing incidence of genetic disorders and increasing prevalence of cancer are driving the gene therapy market growth in the Europe region. These include hemophilia, spinal muscular atrophy, and inherited retinal disorders which continue to be a main focus for therapy development. Gene-based therapies for solid tumors and blood cancers are being developed for the rising burden of cancer, the increasing financial investment by biotech corporations, more rapid uptake of newer therapies, and have the potential to increase the number of patients and the healthcare system’s ability to adopt advanced therapies.
Improved targeting, safety, and scalability of gene therapies are being developed through improved gene editing technologies such as CRISPR and better adeno-associated virus (AAV) vectors. Non-viral gene delivery techniques may also help ease delivery of these therapies. Digital technologies and automation are improving the efficiency and lowering the costs of advanced therapy production and expanding the types of diseases that can be treated from rare inherited conditions to more common diseases, establishing confidence of regulatory approval in the UK, Europe and beyond.
Growth in biopharmaceutical company capacity, particularly in Germany, is contributing to growth in the bioprocessing market as companies invest in their own sites, capabilities, and partnerships to expand their product pipelines. In this regard, collaboration with research institutions and start-ups is translating early-stage science into potential products. Rapid consolidation in the industry is driven by acquiring new product candidates. As a result of such competition, ATMP therapies may become more widely available and commercialized across Europe over the coming years.
Market Segmentation
Gene Type:
- Antigen: Target genes that stimulate immune response.
- Cytokine: Genes that regulate immune system cell signaling.
- Tumor Suppressor: Genes helping prevent cancer development.
- Suicide Gene: Genes inducing cell death in targeted treatments.
- Deficiency: Genes addressing genetic deficiencies.
- Growth Factors: Genes promoting cell growth and healing.
- Receptors: Genes encoding cellular receptor proteins.
- Others: Additional gene types not classified above.
Vector Type:
- Viral Vector:
- Adenoviruses: Viruses used to deliver genetic material.
- Lentiviruses: Vectors derived from lentiviruses for gene delivery.
- Retroviruses: Retrovirus-based vectors facilitating gene insertion.
- Adeno-Associated Virus: Widely used viral vector.
- Herpes Simplex Virus: Virus used in gene delivery.
- Poxvirus: Virus vectors employed for therapeutic purposes.
- Vaccinia Virus: Used as gene therapy vectors.
- Others: Additional viral vectors.
Non-Viral Techniques:
- Naked and Plasmid Vectors: Non-viral DNA delivery methods.
- Gene Gun: Physical method to deliver genetic material.
- Electroporation: Technique using electric pulses for gene transfer.
- Lipofection: Lipid-mediated gene delivery.
- Others: Other non-viral delivery techniques.
Delivery Method:
- In-Vivo Gene Therapy: Direct delivery into the patient’s body.
- Ex-Vivo Gene Therapy: Cells modified outside the body and reintroduced.
- Application:
- Oncological Disorders: Gene therapy for cancer treatment.
- Rare Diseases: Targeting uncommon genetic disorders.
- Cardiovascular Diseases: Therapy for heart-related conditions.
- Neurological Disorders: Treating nervous system diseases.
- Infectious Disease: Gene therapy against infections.
- Others: Additional therapeutic applications.
Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Regional Insights
Germany is a dominant region highlighted in the report, with significant involvement of biopharmaceutical companies investing heavily in research, clinical trials, and partnerships. This investment drives competitive development pipelines and supports rapid approvals and patient access across Europe, contributing to the overall market momentum. Specific regional market share or CAGR statistics were not provided.
Recent Developments & News
In May 2025, EMA’s Committee for Medicinal Products for Human Use recommended conditional marketing authorization in the EU for Aucatzyl (obecabtagene autoleucel), to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukemia in adults, with EU authorization granted in July 2025. Additionally, in November 2024, Genethon announced the initiation of a Phase 3 trial of its Duchenne muscular dystrophy gene therapy, GNT0004, in Europe. Early trial data showed improved motor function in treated boys, with plans for regulatory approval submissions pending positive results.
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
